I-Mab Reports Third Quarter 2024 Results - BioSpace

1 day ago · ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, exclusively focused on the development …

CouponFollow Extension

$184
OFF

I-Mab Reports Third Quarter 2024 Results - Morningstar

1 week from now

2 days ago · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

morningstar.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results - PR Newswire

1 week from now

2 days ago · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

prnewswire.com

$207
OFF

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress

1 week from now

Aug 28, 2024 · First-Half 2024 Financial Results. Cash Position. As of June 30, 2024, the Company had cash and cash equivalents, and short-term investments of $207.5 million, …

biospace.com

$184
OFF

I Mab : Reports Third Quarter 2024 Results - MarketScreener

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Cash Position. As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

marketscreener.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results - Nasdaq

1 week from now

Sep 30, 2024 · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024 , the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

nasdaq.com

$9
OFF

Invivyd Reports Third Quarter 2024 Financial Results And

1 week from now

1 day ago · Third Quarter 2024 Financial Results. Revenue: Reported $9.3 million of net product revenue of PEMGARDA in Q3 2024 as compared to $2.3 million in Q2 2024. Cash Position: …

biospace.com

$853102
OFF

HCW Biologics Reports Third Quarter 2024 Financial Results

1 week from now

1 day ago · Third Quarter 2024 Financial Results. Revenues: Revenues for the quarter ended September 30, 2023 and 2024 were $853,102 and $426,423, respectively. Revenues for the …

biospace.com

$648
OFF

ITeos Reports Third Quarter 2024 Financial Results And

1 week from now

4 days ago · Third Quarter 2024 Financial Results Cash and Investment Position: The Company’s cash, cash equivalents, and investments position was $648.9 million as of September 30, …

globenewswire.com

FAQs about I-Mab Reports Third Quarter 2024 Results - BioSpace Coupon?

How much money did I-MAB invest in 2027?

Key financial highlights reveal I-Mab’s total cash and short-term investments amounted to $184.4 million as of September 30, 2024, providing a financial runway into 2027. ...

How big is I-MAB Biopharma's annual report?

What did I-MAB ADR (iMab) do in Q3?

I-Mab Adr ( (IMAB) ) has released its Q3 earnings. Here is a breakdown of the information I-Mab Adr presented to its investors. I-Mab is a U.S.-based global biotechnology company focused on developing innovative immunotherapies for cancer treatment, recognized for its unique approach to targeting tumor microenvironments. ...

How is I-MAB advancing its uliledlimab and givastomig programs?

Strategically, I-Mab is advancing its uliledlimab and givastomig programs with new phase 2 studies scheduled for 2025. The company also finalized a collaboration agreement with Sanofi and settled previous repurchase obligations, streamlining its operations. ...